TAKE Solutions’ signs up Novel Therapeutics

Deal for deployment of PharmaReady eCTD & SPL Solution Suite

Chennai, September 14, 2009 – TAKE Solutions Ltd. (BSE: 532890), leaders in Supply Chain Management (SCM) and Life Sciences products, has signed a deal with the full-service pharmaceutical company, Novel Therapeutics Pvt. Ltd based at Chennai engaged in “Development, Manufacturing and Marketing” of Generic pharmaceutical formulations specifically dedicated for United States of America (USA) and other regulated markets. This will be TAKE Solutions’ first deal in Chennai for the deployment of the increasingly popular PharmaReady eCTD and SPL solution suite. This comes on the back of successful deals signed for PharmaReady installations and will be TAKE’s 9th client win in the country in the past nine months.

Talking about the deal, Mr. Ramesh L, Vice President – Sales, Life Sciences APAC, TAKE Solutions said, “We are thrilled with this partnership with a highly respectable global player in the drug products market. This also reiterates the fact that the Indian pharma industry has matured enough to realize the benefits of investing in cutting-edge technology solutions for long-term business gains. Being associated with Novel’s aim of providing their customers with niche technology-based drug products also encourages us to think that we are on the right path.”

Mr. J. Jayaseelan, Director Novel Therapeutics Pvt. Ltd. said, “The Pharma Ready eCTD and the SPL solution suite is just the kind of cutting edge technology we were looking for to help us reach our goal of providing new and generic technology-based drug products to the global market. We as a company believe in our ability to use efficient processes and latest technologies for best results and TAKE Solutions seems to be a more than able partner in this journey.”

About TAKE Solutions

TAKE Solutions is a leading international business technology company with products backed by a strong domain expertise in Life Sciences and Supply Chain Management – to provide cost-effective, comprehensive solutions for businesses. The vision of the company is to drive industry best practices through our proprietary, in-depth product know-how and solutions that enable business efficiencies for our clients. Since its inception in 2000, TAKE has been serving marquee clients in the Life Sciences and SCM arena. TAKE Solutions conducts business today in 16 countries with more than 300 customers.

Headquartered in Chennai, TAKE primarily drives its SCM Domain Excellence Centre and Global Delivery Centre from India. Company has strong presence in the USA with Life Sciences Domain Excellence centres located in Princeton, New Jersey.

TAKE Solutions is assessed at Level 5 of the Capability Maturity Model Integration (CMMI) & Level 3 of the People Capability Maturity Model, Software Engineering Institute, Carnegie Mellon University, USA. TAKE Solutions is a Microsoft Gold Certified Partner, a Charter Member of the Microsoft BioIT Alliance, and is a Registered CDISC Solution Provider.
www.TAKESolutions.com
About Novel

Novel Therapeutics Private Limited (NTPL) founded in novembre, 2007 by industry vétéran Mr. J. Jayaseelan, Director. Novel is a 100% Export Oriented Unit (EOU) engaged in “Development, Manufacturing and Marketing” of Generic pharmaceutical formulations specifically dedicated for United States of America (USA) and other regulated markets.

NTPL has a technical tie-up for its R&D activités from well renowned scientists based in USA ably supported by a dozen Senior Scientists working at its Chennai site. NTPL offers the unmatching dual benefits of US technology at Indian Cost.

The NTPL has got state-of-the-art Research & Development (R&D) and Manufacturing facility at Kelambakkam near Chennai, Tamil Nadu, India. The facility has a total built up area of 65000 sq.ft spread over a plot of 3 acres comprising the R&D, Manufacturing.

The R&D and Manufacturing facility is matching with the International Standards. NTPL is working on robust pipeline of its own ANDAs and has a target to achieve valuation of INR 500 Cr in the next five years.

NTPL has recently launched its domestic marketing wing in the name of M/s. Delvin Formulations Pvt. Ltd. where they are planning to lunch lot of unique formulations, which will be first of its kind in Indian market.

www.noveltherapeutics.net